Ash Abstract Dump Poorly Timed For Biotech Investors

Ash Abstract Dump Poorly Timed For Biotech Investors


Ash may not have been the only reason for slumping biotech share prices yesterday, but it didn't help. With drug pricing front and center in a volatile presidential campaign just three trading days away from its conclusion, and news that the US Justice Department might be investigating price fixing in generics drugs, it became a day to move to the sidelines at least until the election has been decided.



from Biotech News